Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.
Associate Scientist
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
Associate Scientist (Chemistry)
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.
April 9, 2024
Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science. “We are excited to welcome […]
January 9, 2024
Factor Bioscience Announces U.S. Department of Defense Grant to Develop Gene-Edited Cell Therapies
-Leverages Factor’s extensively patented mRNA, cell-reprogramming, and gene-editing technologies -Cell therapy candidates will initially be developed for the treatment of Duchenne muscular dystrophy (“DMD”) -Other planned applications include infectious, inflammatory, and autoimmune indications CAMBRIDGE, Mass., January 9, 2024 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, announced […]
February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
-mRNA encoding immunomodulatory proteins IκBα-SR and SOD3 ameliorated symptoms in bacterial pneumonia model -Factor is investigating nebulized mRNA formulations for other therapeutic indications and next-generation vaccine applications CAMBRIDGE, Mass., February 28, 2023 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of […]